INTRODUCTION {#sec1-1}
============

Liver cancer, predominantly hepatocellular carcinoma (HCC), is the fifth most common cancer in men and the ninth in women. It is the second most common cause of death from cancer worldwide.\[[@ref1]\] Although much is known about both the cellular changes that lead to HCC and the etiological agents responsible for the majority of HCC cases (hepatitis B virus, hepatitis C virus, alcohol), the molecular pathogenesis of HCC is still not well understood.\[[@ref2]\] Considerable efforts have been devoted to establish staging systems for HCC by using clinical information and pathological classification to provide information at diagnosis on both survival and treatment options.\[[@ref3][@ref4][@ref5][@ref6]\] However, none of the proposed staging systems encompasses the biological and clinical heterogeneity exhibited by HCCs. One of the important reasons is that these predictive algorithms consider HCCs to be static rather than dynamic entities. They account for the size and number of neoplastic lesions at the time of presentation, yet do not take into account their growth behavior during follow-up, such as tumor doubling time (DT).\[[@ref7]\] It therefore appears axiomatic that improving the classification of HCC patients into groups with homogeneous growth pattern will at least improve the application of currently available treatment modalities and at best provide new treatment strategies.

Over the past 20 years, microarray technology has led to the identification of several molecular signatures in HCC. For example, a 164-gene signature has been reported to predict the clinical behavior of metastatic HCC patients.\[[@ref8]\] Another study established a five-gene score to predict HCC survival after liver resection.\[[@ref9]\] These signatures allow stratification of HCC into several clinically relevant subgroups. Nevertheless, the classification and prediction are still improvable because the high-through microarray contains a large amount of bio-information. Therefore, it is necessary to systematically analyze the expression profiles and explore new molecular signatures.

In order to explore new molecular diagnostic and prognostic biomarkers, we systematically analyzed the gene expression profiles between HCCs and adjacent nontumor tissues in the present study. We demonstrated that 15 cytochrome P450 (CYP) family members could make a distinction between HCCs and nontumor tissues. A four CYP-gene (*CYP1A2*, *CYP2E1*, *CYP2A7*, and *PTGIS*) signature is a useful tool to diagnose HCCs and fast-growing HCCs with high sensitivity and specificity. *CYP2C8* is associated with patient survival in individuals at first diagnosis.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design {#sec2-1}
------------

*Discovery stage:* All the HCC Gene Expression Omnibus (GEO) datasets were collected. Then, a published robust rank aggregation (RRA) method was applied to identify the aberrant genes in HCC development.

*Training stage:* GSE14520 was used as the training set. The diagnostic and prognostic values of aberrant genes were evaluated, and a diagnostic signature was constructed in the training set.

*Testing stage:* GSE36376 and GSE54236 were used as the testing sets. The diagnostic and prognostic values of aberrant genes were further validated in the testing sets.

HCC patient datasets and patient samples {#sec2-2}
----------------------------------------

All the HCC datasets (generated from the Affymetrix Human Genome U133 Plus 2.0 Array) were collected from the publicly available GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). The selection criteria used in this study are as follows: (1) all specimens classified as tissues; cells, serum, or plasma are not included; (2) all the included datasets must contain paired HCC tumors and adjacent noncancerous tissues; (3) sample size should be greater than three pairs; and (4) if there existed data overlapping, the largest sample size was selected. According to the above screening criteria, five datasets were finally included in this study (GSE62232, GSE55092, GSE17548, GSE33006, and GSE6764).\[[@ref10][@ref11][@ref12][@ref13][@ref14]\]

To validate the result from the gene expression profiles above, three other datasets were included. They are Roessler\'s study, Lim\'s study, and Villa\'s study (GEO accession: GSE14520, GSE36376, and GSE54236).\[[@ref7][@ref15][@ref16]\] HCC patients and tumor features are detailed in [Table 1](#T1){ref-type="table"}. It is worth noting that, in Villa\'s study, HCC patients were grouped into four quartiles according to increasing tumor DT: ≤53 days, 54--82 days, 83--110 days, and ≥111 days, respectively. The detailed procedure is as follows:\[[@ref7]\] a new diagnosis of HCC at ultrasound (US) surveillance was eligible if they had a clinical condition that allowed a US-guided liver biopsy of a focal lesion, with the largest lesion biopsied in case of multifocality. To further confirm HCC diagnosis, a CT scan was performed. To measure the growth of lesions, a second CT was performed 6 weeks later. During the 6-week interval, patients did not undergo any specific treatment. This interval is much shorter than the average time to treatment after HCC diagnosis.\[[@ref17][@ref18]\] Therefore, no ethical issues were raised. After the second CT, patients were treated according to international guidelines. Based on these CT values, tumor growth was classified as fast growth (first quartile) or slow growth (other quartiles).

###### 

Clinical characteristics of patients enrolled in this study

  Variables                         Roessler's study GSE14520 (*n*=242)   Lim's study GSE36376 (*n*=240)   Villa's study GSE54236 (*n*=81)   *P*\*
  --------------------------------- ------------------------------------- -------------------------------- --------------------------------- ----------
  Male, *n* (%)                     211 (87.2)                            199 (82.9)                       61 (75.3)                         0.04
  Median age (years) (range)        50 (22-77)                            53 (45-61)                       67 (44-88)                        NA^†^
  HBV infection, *n* (%)            231 (95.5)                            183 (76.3)                       10 (12.3)                         \<0.0001
  Tumor characteristics                                                                                                                      
  Tumor size, median (range) (cm)   7.2 (1.3-17.5)                        3.7 (2.5-6.2)                    5.8 (3.1-7.4)                     NA
  Single nodular, *n* (%)           190 (78.5)                            183 (76.3)                       69 (85.2)                         0.239
  Vascular invasion, *n* (%)        88 (36.4)                             133 (55.4)                       9 (11.1)                          \<0.0001
  BCLC^‡^ stage, 0/A/B/C, *n*       20/152/24/29                          0/139/91/10                      0/56/14/10                        \<0.0001
  Median follow-up (months)         51.7                                  NA                               25                                

\*Chi-square test, NA=Not available, BCLC=Barcelona Clinic Liver Cancer

Acquisition and analysis of gene expression profiles of HCC patients {#sec2-3}
--------------------------------------------------------------------

The raw array data (.CEL files) of five gene expression datasets were retrieved from the GEO database and were uniformly preprocessed using the Robust Multichip Average algorithm for background correction, quantile normalization, and log2-transformation. Then, the differentially expressed genes (DEGs) from each dataset were screened out on the basis of *P* ≤ 0.05 and fold change ≥2.

The interlab reproducibility of the results is often problematic due to the small sample size and other factors (such as pathologic staging and surgical outcome) between the studies. To overcome these limitations, a published RRA method was applied to identify the aberrant genes in HCC development.\[[@ref19][@ref20]\] The new data frame results were constructed with the standard of adjusted *P* value \< 0.05. The operation process can be performed by the Robust Rank Aggreg package in R software (version 3.3.3).

Then, the DEGs were classified into different functional gene groups by using the DAVID functional classification method.\[[@ref21]\] The unsupervised hierarchical clustering of both HCC patients and aberrant genes was performed with R software by using the Euclidean distance and complete linkage method.

Statistical analysis {#sec2-4}
--------------------

The continuous variables were analyzed by *t*-test or rank sum test as appropriate. The categorical variables were analyzed by Chi-square test. Binary logistic regression analysis was performed to identify variables independently associated with HCC. To construct a diagnostic model, the candidate genes were fitted in the multivariate logistic regression in the discovery dataset. Odds ratio (OR) and 95% confidence intervals (CI) were estimated by logistic regression model. To visualize the capacity of the risk signature to discriminate between HCC and non-HCC, we summarized the data in a receiver operating characteristic curve.\[[@ref22]\]

The Cox proportional method was used to identify risk factors for recurrence-free survival (RFS) and overall survival (OS). The RFS was calculated from the date of tumor resection until the detection of tumor recurrence, or last observation. The OS was defined as the length of time between the surgery and death or the last follow-up. Variables with a *P* value \< 0.05 in univariate analysis were included in the final multivariate model. Then, these variables were applied to build a risk signature. Finally, HCC patients were assigned a risk score according to the risk signature and were divided into high- and low-risk groups using the median of the risk score as the cutoff value. The difference in RFS or OS between high- and low-risk groups was demonstrated by Kaplan--Meier method, and the statistical significance was assessed by two-sided log-rank test. Hazard ratio (HR) and 95% CI were estimated by Cox proportional hazards regression model. Statistical analyses were performed with SPSS version 22.0 software (SPSS Inc., Chicago, IL, USA), GraphPad Prism 7 (GraphPad Software, La Jolla, CA), and MedCalc software version 12.2.1 (MedCalc, Mariakerke, Belgium).

RESULTS {#sec1-3}
=======

GEO datasets analysis and candidate gene selection {#sec2-5}
--------------------------------------------------

A total of five datasets were included in our study for comprehensive analysis (GSE62232, GSE55092, GSE17548, GSE33006, and GSE6764). After data processing, 2179 DEGs were found in GSE62232; 2627, 2533, 1993, and 1158 DEGs were found in GSE55092, GSE17548, GSE33006, and GSE6764. Then, the method of RRA was used to integrally calculate the DEGs of the five datasets. Finally, 273 genes were identified as the most significantly differential genes. Detailed information is listed in [Supplementary Table S1](#T2){ref-type="table"}. These 273 genes were classified into different functional gene groups by using the DAVID functional classification method. Finally, 93 of 273 genes were classified into 13 functional groups, of which 15 CYP family genes formed the largest cluster with the highest enrichment score of 8.47. Then, whether these 15 CYP genes had the ability to classify HCC and predict the outcome of HCC were validated.

###### 

Significantly differentially expressed genes after integrated calculating through RRA method

  Gene symbol   Score      Adjusted *P*   Gene symbol     Score      Adjusted *P*
  ------------- ---------- -------------- --------------- ---------- --------------
  Upregulated                             Downregulated              
   SPINK1       5.76E-19   3.15E-14        FCN2           1.19E-17   6.52E-13
   AKR1B10      2.75E-17   1.50E-12        CLEC1B         3.03E-16   1.65E-11
   HMMR         1.52E-15   8.30E-11        SLC22A1        2.12E-15   1.16E-10
   ASPM         5.14E-15   2.80E-10        CXCL14         5.14E-15   2.80E-10
   NDC80        1.89E-14   1.03E-09        FCN3           8.58E-15   4.69E-10
   ROBO1        2.09E-14   1.14E-09        GLS2           1.89E-14   1.03E-09
   CAP2         7.35E-14   4.01E-09        CYP39A1        2.31E-14   1.26E-09
   RACGAP1      1.64E-13   8.97E-09        CYP1A2         4.86E-14   2.65E-09
   CCNB1        2.14E-13   1.17E-08        CYP2B6         5.76E-14   3.14E-09
   TOP2A        2.89E-13   1.58E-08        CNDP1          7.35E-14   4.01E-09
   GPC3         3.89E-13   2.12E-08        CLEC4M         1.53E-13   8.38E-09
   PRC1         4.13E-13   2.26E-08        C9             2.43E-13   1.32E-08
   RRM2         4.88E-13   2.66E-08        CXCL12         4.13E-13   2.26E-08
   SPP1         1.19E-12   6.51E-08        APOF           7.04E-13   3.84E-08
   DNAJC6       1.42E-12   7.78E-08        ESR1           7.78E-13   4.25E-08
   KIF20A       1.55E-12   8.48E-08        CRHBP          1.19E-12   6.51E-08
   IGF2BP3      1.62E-12   8.84E-08        TENM1          1.25E-12   6.81E-08
   PRR11        2.17E-12   1.18E-07        GHR            1.42E-12   7.78E-08
   MAP2         4.74E-12   2.59E-07        DNASE1L3       1.62E-12   8.86E-08
   CDKN2C       7.05E-12   3.85E-07        ADRA1A         1.84E-12   1.01E-07
   DLGAP5       8.25E-12   4.50E-07        LPA            1.92E-12   1.05E-07
   NUSAP1       1.18E-11   6.44E-07        HGF            2.44E-12   1.33E-07
   BIRC5        2.03E-11   1.11E-06        HAO2           3.08E-12   1.68E-07
   KIF4A        2.74E-11   1.50E-06        IL1RAP         3.08E-12   1.68E-07
   NCAPG        3.24E-11   1.77E-06        HAMP           4.62E-12   2.52E-07
   CCNB2        3.81E-11   2.08E-06        IGF1           6.20E-12   3.39E-07
   MAGEA1       4.26E-11   2.33E-06        LIFR           7.05E-12   3.85E-07
   KIF11        5.41E-11   2.95E-06        CYP2C8         7.51E-12   4.10E-07
   AURKA        6.52E-11   3.56E-06        NAT2           8.25E-12   4.50E-07
   SULT1C2      7.39E-11   4.03E-06        FBP1           1.08E-11   5.90E-07
   CCNA2        8.28E-11   4.52E-06        LCAT           1.18E-11   6.44E-07
   CDK1         1.14E-10   6.24E-06        GBA3           1.64E-11   8.98E-07
   E2F8         1.76E-10   9.63E-06        NNMT           1.69E-11   9.23E-07
   CCNE2        2.01E-10   1.10E-05        MARCO          1.88E-11   1.03E-06
   BUB1         2.04E-10   1.12E-05        SLCO1B3        1.89E-11   1.03E-06
   LCN2         2.42E-10   1.32E-05        ALDOB          2.36E-11   1.29E-06
   CENPA        2.80E-10   1.53E-05        RDH16          4.26E-11   2.33E-06
   C1orf112     3.06E-10   1.67E-05        SPP2           4.65E-11   2.54E-06
   CDKN3        3.45E-10   1.88E-05        CD5L           6.93E-11   3.78E-06
   AKR1C3       3.87E-10   2.11E-05        MT1M           7.97E-11   4.35E-06
   PBK          6.92E-10   3.78E-05        PLAC8          1.16E-10   6.34E-06
   BUB1B        7.55E-10   4.12E-05        COLEC11        1.18E-10   6.45E-06
   ECT2         9.69E-10   5.29E-05        CYP2C9         1.51E-10   8.26E-06
   EDIL3        1.01E-09   5.51E-05        CYP2E1         1.65E-10   9.00E-06
   CDKN2A       1.05E-09   5.71E-05        SRD5A2         1.68E-10   9.15E-06
   DEPDC1       1.11E-09   6.05E-05        GLYAT          2.11E-10   1.15E-05
   KIAA0101     1.21E-09   6.63E-05        HGFAC          2.11E-10   1.15E-05
   TRIM16       1.53E-09   8.36E-05        C8orf4         2.18E-10   1.19E-05
   PRKAA2       2.31E-09   0.000126011     AFM            2.32E-10   1.27E-05
   CDC20        2.54E-09   0.00013875      ZG16           2.36E-10   1.29E-05
   EZH2         2.69E-09   0.00014687      IGFBP3         2.76E-10   1.51E-05
   TTK          3.15E-09   0.000172213     ATF5           3.02E-10   1.65E-05
   LEF1         3.45E-09   0.000188269     SOCS2          3.35E-10   1.83E-05
   ACSL4        4.21E-09   0.000230079     NPY1R          3.71E-10   2.03E-05
   CENPF        5.10E-09   0.00027849      KDM8           4.52E-10   2.47E-05
   DTL          8.21E-09   0.000448485     COLEC10        4.58E-10   2.50E-05
   MELK         9.44E-09   0.000515558     MRC1           5.11E-10   2.79E-05
   CDKN2B       9.76E-09   0.000532784     XDH            5.61E-10   3.06E-05
   NEK2         1.10E-08   0.000603006     STEAP4         6.15E-10   3.36E-05
   FGF13        1.10E-08   0.000603006     MT1F           6.62E-10   3.62E-05
   COL15A1      1.26E-08   0.000686421     MBL2           6.99E-10   3.82E-05
   CLGN         1.27E-08   0.000692295     SLC7A2         7.17E-10   3.92E-05
   STXBP6       1.85E-08   0.00100832      CYP2C18        7.64E-10   4.17E-05
   ITGA6        2.15E-08   0.001173191     DCN            8.22E-10   4.49E-05
   RRAGD        2.20E-08   0.001199474     STAB2          8.22E-10   4.49E-05
   FAM169A      2.44E-08   0.001333329     CIDEB          8.43E-10   4.60E-05
   MAGEA6       2.44E-08   0.001333329     CYP4A11        9.28E-10   5.07E-05
   PEG10        2.72E-08   0.001483161     CYP2A6         9.30E-10   5.08E-05
   KIF14        2.76E-08   0.001509308     RCAN1          1.30E-09   7.09E-05
   SLC7A11      2.81E-08   0.0015358       SRPX           1.32E-09   7.22E-05
   MAD2L1       3.01E-08   0.001645264     ZGPAT          1.42E-09   7.75E-05
   ENAH         3.44E-08   0.001878771     LY6E           1.45E-09   7.92E-05
   TKT          3.62E-08   0.001976497     VNN1           1.48E-09   8.06E-05
   MAGEA3       4.38E-08   0.002392275     MASP1          1.55E-09   8.46E-05
   PTTG1        4.66E-08   0.002544424     CA2            1.69E-09   9.21E-05
   ZWINT        5.33E-08   0.002913182     KCNN2          1.76E-09   9.63E-05
   CENPU        6.08E-08   0.003320583     CXCL2          2.01E-09   0.000110033
   APOBEC3B     1.17E-07   0.006411243     KBTBD11        2.25E-09   0.000123013
   DLG5         1.80E-07   0.009808666     KAZN           2.34E-09   0.000128026
   TXNRD1       1.94E-07   0.010578678     CETP           3.07E-09   0.000167869
   EFCAB2       4.75E-07   0.025921521     GYS2           3.15E-09   0.000172213
   CKAP2        4.79E-07   0.02614349      MT1G           3.25E-09   0.000177446
   SLC38A6      5.30E-07   0.028919541     MT1H           3.35E-09   0.000182797
   NRCAM        5.90E-07   0.032238372     GPM6A          3.60E-09   0.000196524
   DHRS2        6.29E-07   0.034360482     THBS1          5.29E-09   0.000289149
   TPX2         6.33E-07   0.034574782     AKR1D1         5.81E-09   0.000317473
   FAT1         6.85E-07   0.037402125     MT1E           6.12E-09   0.000334159
   SMPX         8.02E-07   0.043778089     MT1X           6.28E-09   0.000342744
   HOXA3        8.40E-07   0.045901344     HABP2          6.83E-09   0.000373189
                                           GREM2          7.28E-09   0.000397764
                                           PLG            7.64E-09   0.000417031
                                           GSTZ1          7.76E-09   0.000423617
                                           AGXT           9.12E-09   0.000497916
                                           MYO10          9.19E-09   0.000501698
                                           ACSM3          9.33E-09   0.00050933
                                           MOGAT2         9.47E-09   0.000517054
                                           ECM1           9.61E-09   0.000524872
                                           GNMT           9.88E-09   0.000539501
                                           ADH1A          1.05E-08   0.000573787
                                           ADAMTS13       1.18E-08   0.000644603
                                           ANXA10         1.45E-08   0.000794344
                                           TMEM45A        1.58E-08   0.000861452
                                           PDGFRA         1.67E-08   0.000914505
                                           TDO2           1.74E-08   0.000951209
                                           ASS1           1.77E-08   0.000968444
                                           FOS            1.78E-08   0.000969969
                                           SLC10A1        1.85E-08   0.00100832
                                           BBOX1          1.99E-08   0.001088418
                                           AZGP1          2.02E-08   0.00110373
                                           FGFR2          2.15E-08   0.001173191
                                           EPB41L4B       2.32E-08   0.001269561
                                           SH3YL1         2.49E-08   0.001357476
                                           KMO            2.91E-08   0.001589826
                                           C7             3.17E-08   0.00173112
                                           ANGPTL6        3.23E-08   0.001761951
                                           ADH1C          3.58E-08   0.001956276
                                           PRG4           3.62E-08   0.001976497
                                           CD1D           3.73E-08   0.002036314
                                           SLCO4C1        3.99E-08   0.002176958
                                           HBB            4.05E-08   0.002211793
                                           FETUB          4.18E-08   0.002282715
                                           MT1HL1         4.45E-08   0.002429655
                                           MCC            4.80E-08   0.002623161
                                           SHBG           4.87E-08   0.002658396
                                           MT2A           5.49E-08   0.003000286
                                           IGFALS         5.68E-08   0.00310222
                                           RBMS3          6.37E-08   0.003476853
                                           SLC22A7        6.37E-08   0.003476853
                                           PCK1           6.71E-08   0.00366583
                                           CHST4          6.84E-08   0.003733479
                                           HAO1           7.67E-08   0.004187743
                                           OLFML3         9.02E-08   0.004927537
                                           CFP            1.14E-07   0.006235826
                                           FAM134B        1.16E-07   0.006333836
                                           C6             1.20E-07   0.00656818
                                           GRAMD1C        1.47E-07   0.008021078
                                           TFPI2          1.64E-07   0.008980903
                                           TAT            1.70E-07   0.009284924
                                           TRPM8          1.74E-07   0.009491841
                                           CPEB3          1.76E-07   0.009596585
                                           BHMT           1.86E-07   0.010133342
                                           CYP2A7         1.98E-07   0.010806761
                                           CYP26A1        2.06E-07   0.011273951
                                           NDRG2          2.17E-07   0.011875047
                                           SLC1A1         2.36E-07   0.012897255
                                           KCND3          2.41E-07   0.01316171
                                           ADH6           2.58E-07   0.014062978
                                           HAL            2.66E-07   0.014545375
                                           ASPA           3.05E-07   0.016661935
                                           ANK3           3.05E-07   0.016661935
                                           F9             3.08E-07   0.016821456
                                           CYP3A4         3.17E-07   0.017306885
                                           ADH1B          3.58E-07   0.019532585
                                           CYP2C19        3.61E-07   0.019712234
                                           G6PC           3.81E-07   0.020816234
                                           FOSB           3.99E-07   0.021771039
                                           OAT            4.02E-07   0.021965865
                                           ASPN           4.39E-07   0.023986679
                                           ART4           4.47E-07   0.024406973
                                           CYP4F2         4.63E-07   0.025264069
                                           MASP2          4.71E-07   0.025700965
                                           FOLH1B         5.08E-07   0.027737347
                                           ACADL          5.12E-07   0.027970839
                                           NAMPT          5.38E-07   0.029402819
                                           GADD45B        5.56E-07   0.030387478
                                           MFAP3L         5.70E-07   0.031142006
                                           ITGA9          5.94E-07   0.032430592
                                           SLC19A3        6.28E-07   0.03430112
                                           ABCA8          6.80E-07   0.037111871
                                           FAM13A         7.23E-07   0.039481728
                                           PTGIS          8.10E-07   0.044228221
                                           EPB41L4A       8.22E-07   0.044891898
                                           SERPINA4       8.78E-07   0.047971072
                                           KLKB1          8.85E-07   0.048322697
                                           BCHE           9.04E-07   0.049389145

Identification of CYP family genes associated with HCC {#sec2-6}
------------------------------------------------------

Three datasets were used to validate the association between CYP family genes and HCC. They are Roessler\'s study, Lim\'s study, and Villa\'s study (GEO accession: GSE14520, GSE36376, and GSE54236). A total of 242 patients were enrolled in the Roessler\'s study, which is the largest dataset in our study. So, we used this dataset to form a training set. The remaining two were considered as the testing sets. Patients in Villa\'s study were mostly Caucasians, while patients in Roessler\'s study and Lim\'s study were mostly Asians. [Table 1](#T1){ref-type="table"} summarized the clinical characteristics of the patients in the training set and testing sets. There was heterogeneity among these three sets in some characteristics, such as sex distribution, hepatitis B virus infection, vascular invasion, and Barcelona Clinic Liver Cancer (BCLC) stage. Such heterogeneity may help to ensure that molecular signatures have real-world applicability across heterogeneous patient populations. Besides, in Villa\'s study, HCC patients were grouped into fast growing group (*n* = 20) and slow growing group (*n* = 61), according to increasing tumor DT. Kaplan--Meier curve analysis of survival showed a significantly lower survival rate for HCC cases in the fast growing group as compared with HCC cases in the slow growing group (*P* \< 0.0001).\[[@ref7]\]

The expressions of 15 CYP genes in HCC tissues were confirmed in the training set, and the results showed that all of these 15 genes were significantly decreased in HCC tissues as compared to that in the matched nontumor tissues \[[Figure 1b](#F1){ref-type="fig"}\]. Unsupervised hierarchical clustering of 484 tissues according to the expression patterns of these 15 CYP genes showed two distant clusters, which were highly correlated with HCC (*P* = 6.53E - 9, Chi-square test; [Figure 1a](#F1){ref-type="fig"}). Indeed, cluster I contained most of the nontumor tissues (*n* = 236; 97.5%). Conversely, cluster II contained the majority of tumor tissues (*n* = 241; 99.6%).

![Deregulated cytochrome P450 (CYP) family genes in HCC tumor tissues in the training set. (a) The unsupervised hierarchical clustering heat map of 242 HCC samples and 242 matched adjacent nontumor livers; each row represents an individual tissue sample and each column represents the expression level of an individual CYP gene. (b) Relative expression of the 15 CYP genes in 242 HCC tumor tissues and 242 adjacent nontumor tissues. T = Tumor tissues, *N* = nontumor tissues](SJG-25-167-g001){#F1}

Construction of diagnostic signature from the training set and validating this signature in the testing sets {#sec2-7}
------------------------------------------------------------------------------------------------------------

In univariate analysis, all of 15 genes were confirmed to be significantly differentially expressed between HCC tissues and nontumor tissues. In multivariate analysis, 4 of 15 genes reached statistical significance and were used to construct the diagnostic model \[[Table 2](#T3){ref-type="table"}\]. The model was as follows: logit (*P*) = 47.896 − 0.721 × *CYP1A2* − 1.132 × *CYP2E1* − 1.320 × *CYP2A7* − 3.736 × *PTGIS*. The best cutoff point of this model is −0.6513. Possibility above −0.6513 suggested HCC. The area under curve (AUC) for the established four-gene expression signature was 0.991 (95% CI, 0.977--0.997; [Figure 2a](#F2){ref-type="fig"}), higher than the diagnostic value of any of these four genes (the AUCs of *CYP1A2*, *CYP2E1*, *CYP2A7*, and *PTGIS* were 0.973, 0.877, 0.931, and 0.874, respectively).

###### 

Univariate and multivariate logistic regression analysis in the training set

  Genes       Univariate analysis   Multivariate analysis                                     
  ----------- --------------------- ----------------------- --------- ------- --------------- ---------
  *CYP39A1*   0.190                 (0.140-0.257)           \<0.001                           
  *CYP1A2*    0.239                 (0.181-0.316)           \<0.001   0.486   (0.318-0.744)   0.001
  *CYP2B6*    0.115                 (0.079-0.168)           \<0.001                           
  *CYP2C8*    0.004                 (0.001-0.012)           \<0.001                           
  *CYP2C9*    0.036                 (0.018-0.069)           \<0.001                           
  *CYP2E1*    0.183                 (0.122-0.276)           \<0.001   0.322   (0.161-0.644)   0.001
  *CYP2C18*   0.222                 (0.164-0.301)           \<0.001                           
  *CYP4A11*   0.058                 (0.033-0.101)           \<0.001                           
  *CYP2A6*    0.255                 (0.196-0.334)           \<0.001                           
  *CYP2A7*    0.186                 (0.139-0.250)           \<0.001   0.267   (0.151-0.472)   \<0.001
  *CYP26A1*   0.174                 (0.126-0.240)           \<0.001                           
  *CYP3A4*    0.130                 (0.085-0.197)           \<0.001                           
  *CYP2C19*   0.153                 (0.111-0.212)           \<0.001                           
  *CYP4F2*    0.124                 (0.082-0.186)           \<0.001                           
  *PTGIS*     0.007                 (0.003-0.017)           \<0.001   0.024   (0.005-0.111)   \<0.001

OR=Odds ratio, CI=confidence intervals

![Receiver operating characteristic (ROC) curve analysis of the four-gene (*CYP1A2*, *CYP2E1*, *CYP2A7*, and *PTGIS*) signature in the training and testing sets. In order to compare the predictive value of the four-gene signature, we analyzed the ROC curve of the signature in different datasets. ROC plots for the four-gene panel discriminating HCC in the (a) training set, (b) Lim\'s dataset, (c) Villa\'s study; (d) ROC plots for the four-gene panel discriminating between fast-growing HCC and slow-growing HCC. AUC = Area under the curve](SJG-25-167-g002){#F2}

To confirm our findings, the diagnostic ability of the four-gene expression signature was validated in two testing sets. In Lim\'s study, with the same cutoff point, the AUC of the four-gene signature was 0.973 (95% CI, 0.953--0.986; [Figure 2b](#F2){ref-type="fig"}). In Villa\'s study, the four-gene signature could distinguish HCC with an AUC of 0.852 (95% CI, 0.787--0.903; [Figure 2c](#F2){ref-type="fig"}). Moreover, this gene signature had a good performance to make a distinction between fast-growing HCC and slow-growing HCC (AUC = 0.898; 95% CI, 0.810--0.954; [Figure 2d](#F2){ref-type="fig"}), especially for its high sensitivity and specificity (95% and 85.25%, respectively).

Performance of the CYP family genes in HCC outcomes {#sec2-8}
---------------------------------------------------

In the training set, univariate Cox proportional hazard regression was applied to analyze each of the 15 genes. The results showed that 7 of 15 genes were significantly correlated with patient\'s RFS \[[Table 3](#T4){ref-type="table"}\], and another 7 of 15 genes were significantly correlated with patient\'s OS \[[Supplementary Table S2](#T5){ref-type="table"}\]. In multivariate analysis, only *CYP2C8* demonstrated significant correlation between patient\'s RFS (HR = 0.809; 95% CI, 0.712--0.919) and OS (HR = 0.735; 95% CI, 0.634--0.853).

###### 

Cox regression analysis of recurrence-free survival in the training set

  Genes       Univariate analysis   Multivariate analysis                                   
  ----------- --------------------- ----------------------- ------- ------- --------------- -------
  *CYP39A1*   0.922                 (0.823-1.032)           0.158                           
  *CYP1A2*    0.909                 (0.815-1.014)           0.087                           
  *CYP2B6*    0.869                 (0.724-1.043)           0.132                           
  *CYP2C8*    0.809                 (0.712-0.919)           0.001   0.809   (0.712-0.919)   0.001
  *CYP2C9*    0.945                 (0.852-10.48)           0.281                           
  *CYP2E1*    0.974                 (0.920-1.031)           0.357                           
  *CYP2C18*   0.990                 (0.889-1.103)           0.857                           
  *CYP4A11*   0.869                 (0.780-0.967)           0.010                           
  *CYP2A6*    0.899                 (0.834-0.970)           0.006                           
  *CYP2A7*    0.864                 (0.767-0.973)           0.016                           
  *CYP26A1*   0.744                 (0.554-1.000)           0.050                           
  *CYP3A4*    0.868                 (0.774-0.973)           0.015                           
  *CYP2C19*   1.023                 (0.850-1.231)           0.808                           
  *CYP4F2*    0.873                 (0.778-0.980)           0.021                           
  *PTGIS*     0.994                 (0.608-1.625)           0.981                           

HR=Hazard ratio, CI=confidence intervals

###### 

Cox regression analysis of overall survival in the training set

  Genes       Univariate analysis   Multivariate analysis                                   
  ----------- --------------------- ----------------------- ------- ------- --------------- -------
  *CYP39A1*   0.944                 (0.826-1.080)           0.403                           
  *CYP1A2*    0.906                 (0.792-1.035)           0.146                           
  *CYP2B6*    0.890                 (0.714-1.108)           0.295                           
  *CYP2C8*    0.735                 (0.634-0.853)           0.000   0.735   (0.634-0.853)   0.000
  *CYP2C9*    0.868                 (0.770-0.979)           0.021                           
  *CYP2E1*    0.948                 (0.888-1.013)           0.116                           
  *CYP2C18*   0.943                 (0.829-1.072)           0.370                           
  *CYP4A11*   0.776                 (0.683-0.882)           0.000                           
  *CYP2A6*    0.854                 (0.778-0.938)           0.001                           
  *CYP2A7*    0.800                 (0.690-0.926)           0.003                           
  *CYP26A1*   0.779                 (0.553-1.096)           0.152                           
  *CYP3A4*    0.797                 (0.692-0.918)           0.002                           
  *CYP2C19*   1.004                 (0.796-1.267)           0.970                           
  *CYP4F2*    0.832                 (0.724-0.956)           0.010                           
  *PTGIS*     1.087                 (0.605-1.952)           0.780                           

Each patient in the training set was classified into different prognostic groups (the high- and low-risk groups) according to the median value of *CYP2C8 (*6.39). Patients in high-risk group had mean and median RFS periods of 32.841 ± 2.468 and 23 months, respectively, whereas the mean and median RFS periods for patients in low-risk group were 44.960 ± 2.298 and 59.5 months, respectively. Correspondingly, the Kaplan--Meier analysis demonstrated a significant difference in RFS between these two groups (*P* = 0.0009; [Figure 3a](#F3){ref-type="fig"}). Meanwhile, patients in high-risk group had significantly shorter OS period than those in low-risk group (mean 41.239 ± 2.461 vs. 54.519 ± 1.947 months; median 51.6 vs. 64.7 months; *P* \< 0.0001, log-rank test; [Figure 3b](#F3){ref-type="fig"}). Besides, *CYP2C8* was downregulated in BCLC stage B--C when compared with BCLC stage 0--A (*P* = 0.023).

![Kaplan--Meier curve for recurrence-free survival (RFS) and overall survival (OS) in patients with HCC with high- or low risk according to the median value of *CYP2C8*. (a, b) RFS and OS in the training set, and (c) OS in Villa\'s set](SJG-25-167-g003){#F3}

Cox regression analysis identified *CYP2C8* (HR = 0.865; 95% CI, 0.754--0.992; *P* = 0.038), Tumor Node Metastasis (TNM) stage (HR = 1.641; 95% CI, 1.195--2.254; *P* = 0.002), and BCLC stage (HR = 1.760; 95% CI, 1.312--2.360; *P* \< 0.0001) as independent risk factors for RFS. *CYP2C8* (HR = 0.849; 95% CI, 0.716--0.995; *P* = 0.033), TNM stage (HR = 1.723; 95% CI, 1.189--2.498; *P* = 0.004), and BCLC stage (HR = 1.582; 95% CI, 1.120--2.236; *P* = 0.009) were also independent risk factors for OS.

Moreover, Villa\'s dataset was used to validate the prognostic efficiency of *CYP2C8*. Patients were classified into high- and low-risk groups with the same cutoff point. Patients in high-risk group had mean and median OS periods of 20.450 ± 2.553 and 19 months, respectively, whereas the mean and median OS periods for patients in low-risk group were 39.217 ± 2.440 and 47 months, respectively. Kaplan--Meier curve analysis of survival showed a significantly lower survival rate for patients in high-risk group (*P* = 0.004, [Figure 3c](#F3){ref-type="fig"}).

DISCUSSION {#sec1-4}
==========

Progression of HCC often leads to vascular invasion and intrahepatic metastasis, which correlate with recurrence after surgical treatment and poor prognosis. Surgical resection and liver transplantation are the only curative treatments for HCC, but eligibility is uncommon. Even if patients underwent surgery, tumor recurrence occurs in more than 70% of cases within 5 years, and the 5-year survival rate is 60--70%.\[[@ref23][@ref24]\] In the past years, great efforts have been made to improve our understanding of the possible mechanism of progression, metastasis, and recurrence at protein, mRNA, and noncoding RNA levels, which will enable them to benefit from adjuvant therapy.\[[@ref25][@ref26]\] More recently, many molecular tools have been developed to assist in patient stratification and prediction with microarray analysis.\[[@ref8][@ref9][@ref15]\] Nevertheless, the classification and prediction are still improvable because the high-through microarray contains a large amount of information. Moreover, gene expression patterns and their prognostic value for HCC have not been systematically investigated.

In this study, we have demonstrated that 15 CYP family genes were significantly decreased in HCC tissues as compared to that in the matched nontumor tissues. A four-gene diagnostic signature was constructed for distinguishing between HCC and noncancerous liver, and the results were robust. Besides, *CYP2C8* was identified as an independent risk factor of survival.

Till now, there are several studies about integrated analysis of gene expression profiles in HCC.\[[@ref27][@ref28][@ref29][@ref30][@ref31]\] But the integration strategies are different. In a study by Shiraishi *et al*. the authors performed integrated and comparative analyses of whole genomes and transcriptomes of 22 HBV-related HCCs and their matched controls. The results showed that various types of genomic mutations triggered diverse transcriptional changes.\[[@ref27]\] In another study, the Wang *et al*. repurposed 7 GEO datasets, which include a total of 267 HCC samples and 67 control samples and then reanalyzed the different genes in these 2 groups.\[[@ref28]\] Zheng *et al*. only used one GEO dataset\[[@ref29]\] while Chen *et al*. used three GEO datasets and one miRNA dataset to obtain DEGs and miRNAs.\[[@ref30]\] In the study by Zhou *et al*. the authors chose four datasets, because they thought these datasets represented different racial populations.\[[@ref31]\] In our study, gene expression profiles have been obtained by repurposing five GEO datasets. Although each of the five datasets used Affymetrix Human Genome U133 Plus 2.0 Array to analyze gene expression patterns, the interlab reproducibility of the results is often problematic due to the small sample size and other factors (such as pathologic staging and surgical outcome). To overcome these limitations, RRA approach was applied in this study. It has been specifically designed for comparison of several ranked gene lists and identification of commonly overlapping genes. This method assigns a *P* value to each element in the aggregated list indicating how much better it is ranked compared with a null model expecting random ordering. Finally, 273 genes were identified as the most significantly differential genes. This method has some strength. Most importantly, it is based on a statistical model that naturally allows evaluating the significance of the results. In addition, RRA is easy to compute and robust, not restricting its use to certain subset of problems or requiring all data to be of top quality. This method can also handle variable gene content of different microarray platforms. By defining the rank vector for each gene based only on the datasets where it is present, we do not have to omit the genes that are not present in every platform.\[[@ref20]\]

In the four-gene signature, the observation of low *CYP1A2* expression in HCC was also reported by other studies.\[[@ref32][@ref33]\] CYP1A2 metabolizes 17β-estradiol to generate the potent antitumor agent 2-methoxyestradiol in HCC. The reduction of CYP1A2 significantly disrupts this metabolic pathway, contributing to the progression and growth of HCC.\[[@ref33]\] The results of previous studies also suggest that functional relationship occurs among genes characterizing the signature identified in this study. Fan *et al*. reported that *CYP2E1* revealed low level of expression in 70% of the tumor tissues, when compared to the adjacent nontumor tissues, at both mRNA and protein levels. The low expression of *CYP2E1* was significantly correlated with the aggressive tumor phenotype, including poor differentiation status, absence of tumor capsule, and younger age of the patients.\[[@ref34]\] Moreover, HBx inhibits human *CYP2E1* gene expression via downregulating HNF4α, which contributes to promotion of human hepatoma cell growth.\[[@ref35]\] However, *CYP2A7* and *PTGIS* are poorly studied in HCC, and further research may reveal a better understanding of the interaction of HCC and these genes.

Lastly, by using multivariate Cox proportional hazard regression analysis, our study demonstrated that only 1 (*CYP2C8*) of 15 genes was significantly correlated with patient\'s RFS and OS. Even so, the multivariate analysis with HRs indicated that *CYP2C8* is a significant survival-related risk factor independent of the well-known BCLC staging system. This implies that HCC prognosis could be improved by the combination of *CYP2C8* with the existed staging system. However, the mechanisms of *CYP2C8* in HCC remain unclear.

A major strength of our study is that the samples were derived from three large populations with different races, which ensured that molecular signatures have real-world applicability. Another advantage of our study is that the rigorous data-processing methods and statistical analysis made our results reliable. Nonetheless, there are also limitations in our study. First, in order to measure the growth of lesions, a second CT was performed 6 weeks later. During the 6-week interval, patients did not undergo any specific treatment. This interval is much shorter than the average time to treatment after HCC diagnosis. Therefore, no ethical issues were raised. But this interval could not be compared with average waiting time for treatment as this usually varies due to unintended reasons. Second, our work needs to be re-evaluated in a special cohort of patients with a proper follow-up or in case-control studies. The signatures should be validated in qRT-PCR-based samples; we therefore need to develop the signatures in tissues with qRT-PCR method. Besides, we did not study the mechanisms of the screened CYP family genes; whether these genes can affect the biological functions of HCC cells remains to be studied.

CONCLUSION {#sec1-5}
==========

A four-gene signature was identified as being able to discriminate between HCC and nontumor tissues as well as identify a subgroup of patients with rapidly growing HCC. Moreover, *CYP2C8* can be used as an independent prognostic risk factor. These results may not only help to identify HCC patients at high risk of rapid growth and recurrence but could also provide insight into the mechanisms of HCC progression, metastasis, and recurrence.
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